Business Wire

Leonard A. Lauder Decides Not to Stand for Re-Election to The Estée Lauder Companies Board of Directors

24.8.2023 23:25:00 EEST | Business Wire | Press release

Share

The Estée Lauder Companies announced today that Chairman Emeritus Leonard A. Lauder has informed the Company of his decision not to stand for re-election to the Company’s Board of Directors (the “Board”) at the annual meeting in November. Leonard Lauder remains Chairman Emeritus of the Company. Pursuant to the stockholders’ agreement among Lauder family members and the Company, Leonard Lauder has the right to designate two directors of the Company. In addition to his son William P. Lauder, who serves as Executive Chairman, Leonard Lauder has designated his son Gary M. Lauder to serve on the Board. The Board has nominated Gary Lauder and will include his name among the nominees for election at the Company’s annual meeting in November. Gary Lauder is the Managing Director of Lauder Partners LLC, a Silicon Valley-based venture capital firm. He has been a venture capitalist since 1985, investing in over 150 private companies. Gary serves on the Board of Governors of Alzheimer’s Drug Discovery Foundation and holds a BA in International Relations from the University of Pennsylvania; a BS in Economics from the Wharton School; and an MBA from the Stanford Graduate School of Business. Gary has periodically attended the Company’s Board meetings over the years as an invited observer, which has provided him with a long-term view of the Company.

Leonard Lauder formally joined The Estée Lauder Companies in 1958 and served as President from 1972 to 1995 and as Chief Executive Officer from 1982 to 1999. He became Chairman of the Board in 1995 and served in that role through June 2009, until he was appointed Chairman Emeritus for the Company. As Chairman Emeritus, Leonard Lauder provides his advice and counsel on a variety of business topics including brand building, marketing, and understanding the global luxury consumer. He continues to play an active role as “Chief Teaching Officer,” educating leaders throughout the Company with his brand symposiums and through speaking engagements with global employees.

“My father envisioned and helped drive the growth and expansion of our Company from an iconic single brand to the global, brand-building powerhouse it is today. We’ve never wavered from his vision of being a home for the best brands and best people, all of whom are united in delivering high-quality, prestige beauty products and high-touch service and experiences, while maintaining our unique, values-driven culture,” said William P. Lauder, Executive Chairman. “It has been an incredible honor and privilege to have worked with and learned from my father over the years. I look forward to continuing to learn from him and know his passion for this industry, this Company, our employees and our consumers is as strong as ever.”

“It has been an honor and privilege to serve on the Board of the Company my mother and father created over 75 years ago,” said Leonard Lauder. “This Board is one of the best in the business. I feel confident that the Company’s leadership and Board will continue to guide our strategy to deliver long-term growth. Additionally, I continue to believe in the success of our Company through the skillful and thoughtful management by William, Fabrizio, and the entire leadership team. The nomination of Gary to the Board further reflects my family’s long-term stewardship, and our support of the vision, values, and people who will drive the Company’s future success. As Chairman Emeritus of the Company, I’m looking forward to continuing my work as advisor and “Chief Teaching Officer,” serving what I believe to be the best Company in the world.”

“On behalf of the Board, I share my deep admiration and appreciation to Leonard for his invaluable contributions to the Company as an officer and as a member of the Board. He is a visionary whose creative thinking is unmatched in the industry. His innovative insights will continue to serve as inspiration for us all,” said Charlene Barshefsky, the Company’s Presiding Director.

In addition to his activities with The Estée Lauder Companies, Leonard Lauder is extremely involved in the worlds of education, art, politics, and philanthropy. He is a Charter Trustee of the University of Pennsylvania and a founding member of the Board of Governors of its Joseph H. Lauder Institute of Management and International Studies. Leonard Lauder became a Trustee of the Whitney Museum of American Art in New York City in 1977 and currently serves as its Chairman Emeritus. He is Co-Founder and Co-Chairman of the Alzheimer’s Drug Discovery Foundation; Honorary Chairman of the Breast Cancer Research Foundation; a member of the Council on Foreign Relations; a Trustee of the Aspen Institute; and a member of the President’s Council of Memorial Sloan-Kettering Hospital. Leonard Lauder also served on the Advisory Committee for Trade Negotiations under President Ronald Reagan. Among his honors, he has been named an Officier de la Légion d’Honneur by France and recognized by the U.S. Navy Supply Corps Foundation with its Distinguished Alumni Award, was the 2013 recipient of the Palazzo Strozzi Renaissance Man of the Year Award, and was named a 2014 Living Landmark by the New York Landmarks Conservancy.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors: Rainey Mancini
rmancini@estee.com

Media: Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings & Gatbits IT Infrastructure Announce Launch of GTBS Digital Ecosystem; Mainnet Set for April 202630.3.2026 21:30:00 EEST | Press release

The Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings, in collaboration with Gatbits IT Infrastructure, has officially announced the launch of the GTBS Digital Ecosystem, marking a significant step forward in the global Web3 space. The announcement follows the successful launch of the native GTBS Coin on December 25, with the ecosystem’s mainnet scheduled to go live in April 2026. GTBS represents a full-stack Web3 ecosystem integrating blockchain, artificial intelligence, decentralized finance (DeFi), entertainment, gaming, media, and cloud infrastructure into a unified platform. Built on the philosophy of “All Commitment On Time,” the ecosystem focuses on delivering reliability, scalability, and real-world utility. Designed as a comprehensive digital infrastructure, GTBS goes beyond standalone crypto platforms by offering an integrated environment for users, developers, creators, and enterprises. Its proprietary Layer-1 blockchain powers seamless interaction across se

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye